Nls Pharmaceutics LTD 20-F annual reports
The annual report filed by foreign private issuers listed on a US exchange — the 10-K’s equivalent for non-US companies.
NLS Pharmaceutics reports a net loss and expresses substantial doubt about its ability to continue as a going concern, even as it pursues a merger with Kadimastem to shift its focus to cell therapy.
NLS Pharmaceutics clarifies warrant terms, reports financials, and addresses going concern doubts in its latest filings.